Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer
- VernacularTitle:伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展
- Author:
Hangye GU
1
;
Qing LYU
1
;
Yong CHEN
1
Author Information
1. Key Specialty of Clinical Pharmacy，the First Affiliated Hospital of Guangdong Pharmaceutical University，Guangzhou 510000，China
- Publication Type:Journal Article
- Keywords:
furmonertinib;
epidermal growth factor receptor;
tyrosine kinase inhibitors;
non-small cell lung cancer
- From:
China Pharmacy
2023;34(14):1788-1792
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is mainly non-small cell lung cancer （NSCLC）. NSCLC is often associated with epidermal growth factor receptor （EGFR） gene mutations. Currently， epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKI） are the preferred first-line treatment option for EGFR-mutated NSCLC. Furmonertinib is the second third-generation EGFR-TKI marketed in China， which is developed independently by China. In this review， it is found that furmonertinib has dual activity， strong tumor suppression， high selectivity， and high safety profile， and is effective in the treatment of EGFR-sensitive mutation， EGFR exon 20 T790M resistance mutation， EGFR exon 20 insertion mutation， and central nervous system metastasis NSCLC， and its relevant clinical trials are only enrolled in Chinese patients， which is more guidance for Chinese NSCLC patients in China.
